2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer

US8791113B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Dieter Dorsch · Ober-Ramstadt, DE
• Alfred Jonczyk · Darmstadt, DE
• Guenter Hoelzemann · Seeheim-Jugenheim, DE
• Christiane Amendt · Mühltal, DE
• Frank Zenke · Darmstadt, DE

Key dates

• Filing date: May 31, 2011
• Grant date: Jul 29, 2014
• Expiry date: May 31, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.